1. McCarthy ML, Baum CR. Centrally acting muscle relaxants. In: Brent J, Burkhart K, Dargan P, eds, et al. Critical care toxicology. Cham: Springer, 2017;1133–1141.

2. Okada M, Nose T. Eperisone hydrochloride, a muscle relaxant, is a potent P2X7 receptor antagonist. Chem Pharm Bull (Tokyo) 2024;72:345–348.

3. Iwase S, Mano T, Saito M, Ishida G. Effect of a centrally-acting muscle relaxant, eperisone hydrochloride, on muscle sympathetic nerve activity in humans. Funct Neurol 1992;7:459–470.

4. Mano T, Miyaoka T. Effects of muscle relaxant E.M.P.P. on afferent discharges of muscle spindle in man--an microneurographic analysis (author’s transl). No To Shinkei 1981;33:237–241. 5. Yang SI, Park HY, Lee SH, et al. Transdermal eperisone elicits more potent and longer-lasting muscle relaxation than oral eperisone. Pharmacology 2004;71:150–156.

6. Pinzon RT, Wijaya VO, Paramitha D, Bagaskara RR. Effects of eperisone hydrochloride and non-steroid anti-inflammatory drugs (NSAIDs) for acute non-specific back pain with muscle spasm: a prospective, open-label study. Drug Healthc Patient Saf 2020;12:221–228.

7. Ryu JH, Kim JI, Kim HS, Noh GJ, Lee KT, Chung EK. Pharmacokinetic interactions between pelubiprofen and eperisone hydrochloride: a randomized, open-label, crossover study of healthy Korean men. Clin Ther 2017;39:138–149.

8. Dong JY, Ju JH, Yang YM. Analysis of the prescription trends of potentially inappropriate medications in Korean older outpatients by sex: a retrospective study using data from the health insurance review and assessment service. Medicine (Baltimore) 2023;102:e34818.

9. Hur GY, Park HS. Clinical characteristics of NSAID-induced blended reaction. Allergy Asthma Immunol Res 2021;13:171–172.

10. Ribi C, Vermeulen C, Hauser C. Anaphylactic reactions to tolperisone (Mydocalm). Swiss Med Wkly 2003;133:369–371.

11. Glück J, Rymarczyk B, Rogala B. An immediate hypersensitivity reaction caused by tolperisone hydrochloride. J Investig Allergol Clin Immunol 2011;21:411–412.

12. Lakatos PP, Ignáth Z, Csernák O, Boldizsár I, Szökő É, Tábi T. Separation of tolperisone and its degradation products by a dual cyclodextrin capillary electrophoresis system to study their potential role in allergic events. J Pharm Biomed Anal 2025;252:116532.

13. Cabitza P, Randelli P. Efficacy and safety of eperisone in patients with low back pain: a double blind randomized study. Eur Rev Med Pharmacol Sci 2008;12:229–235.

14. Chandanwale AS, Chopra A, Goregaonkar A, et al. Evaluation of eperisone hydrochloride in the treatment of acute musculoskeletal spasm associated with low back pain: a randomized, double-blind, placebo-controlled trial. J Postgrad Med 2011;57:278–285.

15. Luo L, Yin J, Li Z, et al. Bilateral tonic seizures probably induced by eperisone hydrochloride: a case report. Front Neurol 2023;14:1240526.

16. Yamagiwa T, Amino M, Morita S, Yamamoto R, Saito T, Inokuchi S. A case of torsades de pointes induced by severe QT prolongation after an overdose of eperisone and triazolam in a patient receiving nifedipine. Clin Toxicol (Phila) 2010;48:149–152.

17. Haga Y, Kamijo Y, Yoshizawa T, Hanazawa T, Yokoyama N, Kishino T. QTc prolongation and Torsade de Pointes induced by extreme eperisone overdose. Clin Toxicol (Phila) 2020;58:67–68.

18. Hur GY, Hwang EK, Moon JY, et al. Oral muscle relaxant may induce immediate allergic reactions. Yonsei Med J 2012;53:863–865.

19. Kim SH, Lee J, Kim SH, et al. Anaphylaxis caused by muscle relaxant (eperisone hydrochloride). Allergy Asthma Respir Dis 2013;1:172–175.

20. Kang DY, Lee J, Sohn KH, Kang SY, Cho YS, Kang HR. A case series of eperisone-induced immediate hypersensitivity. Allergy Asthma Respir Dis 2017;5:228–231.

21. Miki Y, Washio K, Masaki T, Nakata K, Fukunaga A, Nishigori C. A case of eperisone hydrochloride-induced anaphylaxis: a true type I reaction? Allergol Int 2017;66:152–153.

22. Park KH, Lee SC, Yuk JE, Kim SR, Lee JH, Park JW. Eperisone-induced anaphylaxis: pharmacovigilance data and results of allergy testing. Allergy Asthma Immunol Res 2019;11:231–240.

23. Shin B, Yoon SY, Lee JH, et al. Clinical characteristics of eperisone-induced immediate-type hypersensitivity. Asian Pac J Allergy Immunol 2020;38:279–285.

24. Liang L, Park KH, Lee JH, Park JW. Causes and diagnostic usefulness of tryptase measurements for anaphylaxis in a Korean tertiary care general hospital. Yonsei Med J 2022;63:1099–1105.

25. Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013;68:702–712.

26. Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol 2022;150:1333–1393.

27. Iammatteo M, Blumenthal KG, Saff R, Long AA, Banerji A. Safety and outcomes of test doses for the evaluation of adverse drug reactions: a 5-year retrospective review. J Allergy Clin Immunol Pract 2014;2:768–774.

28. Barbaud A, Garvey LH, Torres M, et al. EAACI/ENDA position paper on drug provocation testing. Allergy 2024;79:565–579.

29. Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003;58:854–863.

30. Romano A, Atanaskovic-Markovic M, Barbaud A, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy 2020;75:1300–1315.

31. van der Poorten MM, Walschot M, Faber M, et al. Reliability of early and late testing for suspected perioperative hypersensitivity. J Allergy Clin Immunol Pract 2022;10:1057–1062e2.

32. Losappio LM, Cappai A, Arcolaci A, et al. Anxiety and depres sion effects during drug provocation test. J Allergy Clin Immunol Pract 2018;6:1637–1641.

33. Lombardi C, Gargioni S, Canonica GW, Passalacqua G. The nocebo effect during oral challenge in subjects with adverse drug reactions. Eur Ann Allergy Clin Immunol 2008;40:138–141.

34. Beck SC, Wilding T, Buka RJ, Baretto RL, Huissoon AP, Krishna MT. Biomarkers in human anaphylaxis: a critical appraisal of current evidence and perspectives. Front Immunol 2019;10:494.

35. Simons FE, Ardusso LR, Bilò MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 2011;4:13–37.

36. Vitte J, Amadei L, Gouitaa M, et al. Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: an observational study. Allergy 2019;74:1157–1165.

37. Muraro A, Worm M, Alviani C, et al. EAACI guidelines: anaphylaxis (2021 update). Allergy 2022;77:357–377.

38. Mayorga C, Çelik GE, Pascal M, et al. Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper. Allergy 2024;79:580–600.

39. Santos AF, Alpan O, Hoffmann HJ. Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice. Allergy 2021;76:2420–2432.

40. Kim SY, Kim JH, Jang YS, et al. The basophil activation test is safe and useful for confirming drug-induced anaphylaxis. Allergy Asthma Immunol Res 2016;8:541–544.